The Company is a biotechnology innovator revolutionising eczema treatment through its novel peptide-based therapies. With a focus on safe and effective solutions for inflammatory skin conditions, particularly atopic dermatitis (eczema), it is addressing a major unmet need in the market.
- Asking Price:
- Undisclosed
- Turnover:
- £100K - £200K
- Net Profit:
- Under £50K
